The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Cancidas



Merck Sharp & Dohme BVEU/1/01/196/003

Main Information

Trade NameCancidas
Active SubstancesCaspofungin
Dosage FormPowder for concentrate for solution for infusion
Licence HolderMerck Sharp & Dohme BV
Licence NumberEU/1/01/196/003

Group Information

ATC CodeJ02AX Other antimycotics for systemic use
J02AX04 caspofungin

Status

License statusAuthorised
Licence Issued24/10/2001
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back